COMMUNIQUÉS West-GlobeNewswire

Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
16/03/2026
MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in heavily pretreated [...]
Weight Watchers Announces Fourth Quarter and Full Year 2025 Results
16/03/2026
2025 Total Revenue and Adjusted EBITDA 1,2 above high end of previously provided guidance Total End of Period Subscribers of 2.8 million; End of Period Clinical Subscribers of 130 thousand, up 42% year-over-year with [...]
Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026
16/03/2026
WATERTOWN, Mass., March 16, 2026 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms [...]
Cronos Group Inc. to Speak at the 38th Annual ROTH Conference
16/03/2026
TORONTO, March 16, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”), an innovative global cannabinoid company, today announced that Mike Gorenstein, Chairman, President [...]
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
16/03/2026
JUPITER, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free [...]
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine
16/03/2026
- 12-patient cohort fully enrolled with an average time since transplant of approximately 8 months - 100% insulin independence achieved in 10 patients who are over 4 weeks post-transplant - No signs of graft rejection [...]
NRx Pharmaceuticals (Nasdaq:NRXP) Confirms Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
16/03/2026
NRx has received confirmatory FDA minutes from in-person Type C meeting attended by leadership of FDA Division of Psychiatry, FDA Office of Neuroscience, and FDA Center for Drug Evaluation and Research. Minutes are [...]
Novo Nordisk A/S - share repurchase programme
16/03/2026
Bagsværd, Denmark, 16 March 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 ( [...]
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
16/03/2026
Financing led by The Venture Collective with participation from Merck Global Health Innovation Fund, Artis Ventures, First Spark Ventures, argenx, Droia Ventures and existing investors SANTA CRUZ, Calif., March 16, 2026 [...]
Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01
16/03/2026
STAFFORD, Texas, March 16, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is [...]
Quipt Home Medical Completes the Previously Announced Arrangement With Affiliates of Kingswood and Forager
16/03/2026
CINCINNATI, March 16, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ” or “ Quipt ”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, is [...]
SAFE - Modification de la composition du Conseil d'Administration
16/03/2026
Modification de la composition du Conseil d'Administration Fleurieux-sur-l’Arbresle - France - le 16 mars 2026 à 8h. SAFE Group annonce des évolutions significatives au sein de son Conseil d'Administration. Cooptation d [...]
GN Store Nord A/S enters into agreement to sell its Hearing business to Amplifon S.p.A. for DKK 17.0 billion
16/03/2026
Today, GN Store Nord A/S (“GN”) has entered into a definitive agreement for the sale of GN’s Hearing business to Amplifon S.p.A. (“Amplifon”), a leading global hearing care retailer. The transaction values the Hearing [...]
EssilorLuxottica and Dolce&Gabbana further strengthen their partnership through 2050
16/03/2026
EssilorLuxottica and Dolce&Gabbana further strengthen their partnership through 2050 Paris, France and Milan, Italy (16 March 2026) - EssilorLuxottica and Dolce&Gabbana announced today the extension of the [...]
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
16/03/2026
ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the purchase of ordinary shares by a member of the Company’s Board of Directors. Attachments notification-of-managers-transaction [...]
OSE Immunotherapeutics Announces its 2026 Financial Calendar
16/03/2026
Nantes, France, March 16, 2026 – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced its financial calendar for 2026. Information Date* 2025 Full-Year Financial Update and Statements [...]
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
16/03/2026
ZUG, Switzerland, March 16, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical [...]
BioVersys Receives Green Light from US FDA for BV100 HABP/VABP Phase 3 Pivotal Trial Start
16/03/2026
Ad hoc announcement pursuant to Art. 53 LR BV100 is a potential best-in-class anti-infective agent in treating hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP), caused by [...]
EssilorLuxottica et Dolce&Gabbana renforcent leur partenariat jusqu’en 2050
16/03/2026
EssilorLuxottica et Dolce&Gabbana renforcent leur partenariat jusqu’en 2050 Paris, France et Milan, Italie (16 mars 2026) - EssilorLuxottica et Dolce&Gabbana annoncent l’extension de leur accord de licence jusqu [...]

Pages